Clinical Study

Gsk 2019N411039- Phase Ib Trial To Evaluate The Efficacy And Safety Of Bintrafusp Alfa (M7824) Monotherapy In Metastatic Or Locally Advanced/Unresectable Urothelial Cancer With Disease Progression Or Recurrence Following Treatment With A Platinum Agent

Posted Date: Sep 7, 2020

  • Investigator: Shuchi Gulati
  • Specialties: Cancer, Oncology
  • Type of Study: Drug

The purpose of this study is to evaluate bintrafusp alfa in participants with metastatic or locally advanced urothelial cancer. This trial provides the first evaluation of bintrafusp alfa in participants with urothelial cancer that has progressed following platinum therapy. The primary outcome of this study is to determine overall response rate.

Criteria:

To Be Eligible: Must Have Confirmed Locally Advanced Or Metastatic Or Locally Advanced/Unresectable Urothelial Carcinoma, Ecog 0-1, Life Expectancy >12 Weeks, No Other Malignancy Within 3 Years, No More Than 2 Lines Of Systemic Therapy For The Treatment Of Metastastic Disease, History Of Organ Transplant, Significant Active Or Past Medical History That May Impair Ability To Take Study Treatment/Affect Results,

Keywords:

Urothelial Cancer, Phase 1

For More Information:

Uc Cancer Center
513-584-7698
cancer@uchealth.com


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.